Trial Information
Utility of Whole-Body 18-Fluorodeoxyglucose Positron Emission Tomography (PET) In the Pre-Operative Assessment of Patients With Hepatic Colorectal Metastases
Inclusion Criteria:
- initial diagnosis of colorectal carcinoma confirmed by the Pathology Department of
Memorial Hospital or by diagnostic barium enema if the primary tumor is still in
place.
- a candidate for liver resection for metastatic colorectal cancer as defined by
members of the Department of Surgery of Memorial Hospital. Patients with metastatic
colorectal cancer isolated to the colon, rectum, or liver are eligible. In addition,
patients with limited, resectable pulmonary metastases are eligible.
Exclusion Criteria:
- Patients must not be pregnant; females of child bearing age must use an adequate form
of contraception.
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
To assess if whole body 18F-FDG-PET enhances our ability to detect metastatic colorectal cancer restricted to liver and lung over conventional imaging such as CT and to determine the accuracy of PET in imaging extrahepatic tumors.
Outcome Time Frame:
conclusion of the study
Safety Issue:
No
Principal Investigator
Yuman Fong, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Memorial Sloan-Kettering Cancer Center
Authority:
United States: Institutional Review Board
Study ID:
98-015
NCT ID:
NCT00588549
Start Date:
July 1998
Completion Date:
March 2009
Related Keywords:
- Colorectal Carcinoma
- Carcinoma
- Colorectal Neoplasms
- Neoplasm Metastasis
Name | Location |
Memorial Sloan-Kettering Cancer Center |
New York, New York 10021 |